Health Security

Strong public health systems reduce vulnerability to infectious diseases.

Burnet’s Health Security Program works to increase the capacities of health systems across the Asia-Pacific region.

Major components of this Program are aimed at improving responses to drug-resistant tuberculosis, strengthening policies and practices to prevent and control antimicrobial resistance, and applying One Health approaches to improve health for humans, animals and the environment.

Through this program Burnet is committing to making a major contribution:

  • To improve understanding of infectious disease threats and apply new tools to improve health security
  • To contribute to strengthening core public health system capacities required to prepare for and respond to infectious disease threats in the Asia-Pacific region
  • To make a major contribution to respond to tuberculosis, especially drug resistant tuberculosis, in the Asia-Pacific region
  • To increase the capacity of health professionals, researchers, policy makers and the general community in relation to health security, through education and training in Australia, our region and globally.

Contact Details

Doctor Ben Coghlan

Co-Program Director, Health Security

Telephone

+61392822177

Email

[email protected]


Projects

  • ACE2 inhibitors for treatment of COVID-19

  • Age-related immune dysfunction may underpin poor COVID-19 outcomes in the elderly

  • ANCP – Kickstarting antimicrobial resistance responses in PNG (KICK AMR)

  • APPRISE - Centre for Research Excellence

  • Australia Awards Fellowship: KICK-AMR to Address Antimicrobial Resistance

  • Building a Centre of Excellence for Research and Training for DR-TB in Daru, Papua New Guinea

  • Building capacity and improving tuberculosis diagnosis in Timor-Leste

  • Characterisation of retroviruses in bats

  • COVID-19 antigens for PoC test development

  • COVID-19 Vaccine Development

  • Demonstrating the impact of next generation Cepheid tools in TB

  • Diagnostic accuracy of Molbio Truenat for diagnosis of TB and rifampicin resistance

  • ESCAPE-TB: Enhanced screening and preventive therapy for TB in Daru, PNG

  • Intrinsic host antiviral activity against pathogenic viruses

  • National COVID-19 Clinical Evidence Taskforce

  • Neutralising antibody assays for COVID-19

  • Novel reagents for the serological diagnosis of tuberculosis

  • Predicting quality and potency of monoclonal and natural antibodies

  • Rapid and accurate diagnosis of TB: New trial in PNG

  • RID-TB Patient Education and Counselling

  • RID-TB: Reducing the Impact of Drug-Resistant TB in Western Province, PNG

  • STRIVE PNG: Stronger Surveillance and Systems Support for Rapid Identification and Containment of Resurgent or Resistant Vector Borne Pathogens in Papua New Guinea

  • Tackling TB and HIV Together in Papua New Guinea

  • The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

  • The production of guidance for the laboratory sector to prepare for emergency situations

  • The Social and Cultural Determinants of TB in Daru [SCuD-TB Daru – Study 1]

  • Zero TB initiative Yogyakarta

Latest News

    05 November, 2020

    Burnet a RESULTS Leader

    Burnet Institute has been acknowledged by RESULTS Australia with a 2020 Leadership Award.

    30 October, 2020

    IMPACT special edition now online!

    Scroll through Burnet’s latest stories in an all-new digital interface in this special COVID-19 edition of IMPACT.